MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--
Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC), announced today that the company's executive leadership
is now pursuing potentially lucrative partnerships with contacts made at
last week's Biotech Showcase in San Francisco.
In order to meet its expansion goals in 2014, RBCC is targeting
promising innovations in personalized medicine and targeted drug
delivery for marketing and development. Both health sectors are expected
by many experts to grow by billions of dollars in the next few years.
RBCC is reaching out to emerging industry leaders that company
executives met last week regarding development partnerships that could
significantly boost the company's bottom line in the new year.
"We want to partner with developers on the cutting edge of healthcare
technology and deliver new breakthroughs to the patients who need them
most," said RBCC CEO Kimberly Palmer. "The companies we are in talks
with now are on the verge of breakthroughs that could change what's
possible in personalized medicine."
One of the driving forces behind this expansion is the inefficient way
in which drugs are currently produced. Because insurance companies are
highly reluctant to pay for drugs that don't work, pharmaceutical
companies are beginning to use data derived from personalized genome
testing to indicate which drugs will work for specific patients—making a
stronger case for payer reimbursement.
With analysts across the globe calling regenerative and personalized
medicine the future of healthcare, RBCC plans to be well-prepared to
capitalize on the growth to come. By acquiring or partnering with
up-and-coming regenerative therapy companies, RBCC plans to compete in
the biotechnology industry alongside NeoStem, Inc. (NYSE:NBS),
Neuralstem, Inc. (NYSE:CUR), Smith & Nephew (NYSE:SNN) and
Pharmaceutical Product Development (NASDAQ:PPDI).
For more information on RBCC's other biotech initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
Source: Rainbow Coral Corp.